Usability of inhaler devices: a parameter currently misused
Keywords:
Usability; Inhaler devices; Respiratory disordersAbstract
Inhalation represents the most convenient route for delivering respiratory drugs. Delivery systems showed a huge technological progress and several pocket inhalers had been engineered over the last decades for clinical use. Despite the growing technological efforts aimed to simplify the inhalation procedures and optimize the therapeutic outcomes, the effectiveness of drug inhalation through inhalers still represents a major challenge in respiratory medicine. Patients may actually incur in different types of critical errors when using all inhalers and are not capable to inhale throughout all devices equally well. Therefore, the choice of the most suitable and convenient device to prescribe still is a critical issue in real life. Usability is the only comprehensive parameter consenting the effective and objective assessment of pocket inhalers’ performance, and allowing their objective comparison and ranking. Unpredictable discrepancies are in fact easily detectable between inhalers (even belonging to the same class) in terms of Usability, independently of the patient’s awareness. The reasons were described and discussed for each class of inhalers presently available. Usability is a multidimensional parameter that is much more multifaceted and complex than usually presumed. Usability takes origin from the integrated, balanced and objective assessment of the role played by several factors from different domains, such as: factors related to patient’s beliefs, to patients’ behavioural components, to device engineering and to the overall cost. Usability is the key parameter for assessing and optimizing the appropriateness of any inhalation treatment through whatever device. Usability would also represent a key investigational instrument for supporting the future development of innovative and more performing inhaler devices objectively.
References
Virchow JC. Guidelines versus clinical practice – which therapy and which device. Respir Med. 2004;98 (suppl B):S28-34.
Virchow JC, Crompton GK, Dal Negro RW, Pedersen S, Magnan A, Seidemberg J, et al. Importance of inhaler devices in the management of airway diseases. Respir Med 2008;102:10-9.
Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002;96:293-304.
Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008;75:18-25.
Chapman KR, Fogarty CM, Peckitt C, Lassen C, Jadayel D, Dederichs J, et al. Delivery characteristics and patients’ handling of two single-dose dry powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis 2011;6:353-63.
Clark AR, Weers JG, Dhand R. The confusing world of dry powder inhalers: It is all about inspiratory pressures, not inspiratory flow rates. J Aerosol Med Pulm Drug Deliv 2020;33:1-11.
Barry PW, O’Callagnan C. The influence of inhaler selection on efficacy of asthma therapies. Adv Drug Deliv Res 2003;55:879-923.
Anderson P. Patient preference for and satisfaction with inhaler devices. Eur Respir Rev 2005;96:109-16.
Schulte M, Osseiran K, Betz R, Wenker M, Brand P, Meyer T, Haidl P. Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD. J Aerosol Med Pulm Drug Deliv 2008;21:321-8.
Barrons R, Pegram A, Borrens A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. AM J Health Syst Pharm 2011;68:1221-32.
Ninane V, Brusselle GG, Louis R, Dupont L, Liistro G, De Baker W, et al. Usage of inhalation devices in asthma and chronic obstructive pulmonary disease: a Delphi consensus statement. Exp Opin Drug Deliv 2014;11(3):313-23.
O’Connor BJ. The ideal inhaler: design and characteristics to improve outcomes. Respir Med 2004;98(suppl A):S10-6.
Crompton GK. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis Suppl 1982;119:101-4.
Dal Negro RW, Longo P, Villanis Ziani O, Bonadiman L, Turco P. Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study. Multidiscip Respir Med 2017;12:13 DOI 10.1186/s40248-017-0096-1-
Jackson WF. Inhalers in asthma. The new perspective. Harwell, Oxfordshire: Clinical Vision Ltd; 1995:1-56.
Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, et al. Comparison of effectiveness of inhaler devices in asthma and chronic obstructive airway disease: a systematic review of the literature. Health Technol Assess 2001;5(26):1-149.
Terzano C. Dry powder inhaler and the risk of error. Respiration 2008;75:14-5.
Kruger P, Ehrlein J, Zier M, Greguletz R. Inspiratory flow resistance of marketed dry powder inhalers. Eur Respir J 2014;44:abstract 4635.
Lavorini F, Fontana GA. Inhaler technique and patient’s preference for dry powder inhaler devices. Expert Opin Drug Deliv 2014;11:1-3.
Haidl P, Heindl S, Siemon K, Bernacka M, Cloes RM. Inhalation device requirements for patients’ inhalation maneuvers. Respir Med 2016;118:65-75.
Buttini F, Brambilla G, Copelli D, Sisti V, Balducci AG, Bettini R, et al. Effect of flow rate on in vitro aerodynamic performance of Nexthaler in comparison with Diskus and Turbohaler dry powder inhalers. J Aerosol Med Pulm Drug Deliv 2016;29:167-78.
Dal Negro RW. Dry powder inhalers and the right things to remember: a concept review. Multidiscip Respir Med 2015;10:13.
Laube B.L, Janssens HM, De Jongh FHC, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37:1308-31.
Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990;65:308-10.
Sanders MJ. Guiding inspiratory flow: Development of the incheck DIAL G16, a tool for improving inhaler technique. Pulm Med 2017;2017:1495867.
Weers J, Clark A. The impact of inspiratory flow rate on drug delivery to the lungs with dry powder inhalers. Pharm Res 2017;34:507-28.
Dal Negro RW, Turco P, Povero M. The contribution of patients’ lung function to the inspiratory airflow rate achievable through a DPIs’ simulator reproducing different intrinsic resistance rates. Multidiscip Respir Med 2021;16:752.
Henriet AC, Marchand-Adam S, Mankikian J, Diot P. Respimat, first soft mist inhaler: new perspectives in the management of COPD. Rev Mal Respir 2010;27:1141-9.
Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med 1999;12 Suppl 1:S19-24.
Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist inhaler. Int J Pharm 2004;283:1-9.
Anderson P. Use of Respimat soft mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2006;1:251-9.
Duarte-de-Araujo A, Teixeira P, Hespanhol V, Correja-de-Sousa. COPD: misuse of inhaler devices in clinical practice. Int J COPD 2019:14 1209-17.
Gustafsson P; Taylor A, Zanen P, Chrystyn H. Can patients use all dry powder inhalers equally well ? Int J Clin Pract Suppl 2005;149:13-8.
Melani AS. Inhalation therapy training: a priority challenge for the physician. Acta Biomed 2007;78:233-45.
Dal Negro RW, Turco P, Povero M. Patients’ usability of seven most used dry-powder inhalers in COPD. Multidiscip Respir Med 2019;14:30 https://doi.org/10.1186/s40248-019-0192-5
Dal Negro RW, Turco P, Povero M. Assessing the Global Usability of Dry Powder Inhalers: Analysis of Six Devices Widely Used for Asthma. J Pulm Med Respir Res 2021;7:064. DOI: 10.24966/PMRR-0177/100064
Chrystyn H. Do patients show the same level of adherence with all dry powder inhalers? Int J Clin Pract Suppl 2005;19-25.
Franks M, Briggs P. Use of a cognitive ergonomics approach to compare usability of a multidose dry powder inhaler and a capsule dry powder inhaler: an open label, randomized, controlled study. Clin Ther 2005;26:1791-9.
Hantulik P, Wittig K, Henschel Y, Ochse J, Vahteristo M., et al. Usage and usability of one powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany. Pneumol Alergol Pol 2015;83:365-77.
Kozma CM, Slaton TL, Monz BU, Hodder R, Reese PR. Development and validation of a patient satisfaction and preference questionnaire for inhalation devices. Treat Respir Med 2005:4:41-52.
Rajan SK, Gogtay JA. Ease-of-use, preference, confidence, and satisfaction with Revolizer, a novel dry powder inhaler, in an Indian population. Lung India 2014;31:366-37416-19.
Miravitlles M, Montero-Caballero J, Richard F, Santos S, Garcia-Rivero JL, Ortega F, et al. A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD. Int J COPD 2016;11:407-15.
Price D. Do healthcare professionals think that dry powder inhalers can be used interchangeably? Int J Clin Pract Suppl 2005;149: 26-9.
Published
Issue
Section
License
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Mattioli 1885 has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
How to Cite
